Selective serotonin reuptake inhibitor toxicity: Difference between revisions
m (Rossdonaldson1 moved page SSRI Toxicity to SSRI toxicity) |
Neil.m.young (talk | contribs) (Text replacement - "==Treatment==" to "==Management==") |
||
(6 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Most serious adverse effect is potential to produce [[Serotonin Syndrome]] | *Most serious adverse effect is potential to produce [[Serotonin Syndrome]] | ||
Line 4: | Line 5: | ||
==Clinical Features== | ==Clinical Features== | ||
* | *[[Nausea and vomiting]] | ||
*Sedation | *Sedation | ||
*Tremor | *Tremor | ||
*Sinus | *[[Sinus tachycardia]] | ||
*QRS, QT prolongation (citalopram only) | *QRS, [[QT prolongation]] (citalopram only) | ||
*[[Serotonin | *[[Serotonin syndrome]] | ||
== | ==Differential Diagnosis== | ||
*[[Serotonin syndrome]] | |||
{{Anticholinergic types}} | |||
==Management== | |||
*GI decontamination | *GI decontamination | ||
**Activated charcoal x1 | **Activated charcoal x1 | ||
Line 20: | Line 25: | ||
==See Also== | ==See Also== | ||
*[[Serotonin syndrome]] | |||
*[[SNRI Toxicity]] | *[[SNRI Toxicity]] | ||
== | ==References== | ||
<references/> | |||
[[Category: | [[Category:Toxicology]] |
Revision as of 05:54, 9 July 2016
Background
- Most serious adverse effect is potential to produce Serotonin Syndrome
- Fatalities are uncommon with pure overdoses
Clinical Features
- Nausea and vomiting
- Sedation
- Tremor
- Sinus tachycardia
- QRS, QT prolongation (citalopram only)
- Serotonin syndrome
Differential Diagnosis
Anticholinergic toxicity Causes
- Medications[1]
- Atropine
- Antihistamines
- Antidepressants
- Antipsychotics
- Muscle relaxants
- Anti-Parkinsonians
- Plants
- Jimson weed (Devil's trumpet)
- Amanita mushroom
Management
- GI decontamination
- Activated charcoal x1
- Gastric lavage unnecessary
Disposition
- Consider admission for patients who are tachycardic or lethargic 6hr after ingesion
See Also
References
- ↑ Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2015;81(3):516-24.